Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: MRA, Chugai.

Changhai Ding1, Graeme Jones

  • 1Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart, 7000 TAS, Australia. changhai.ding@utas.edu.au

Current Opinion in Molecular Therapeutics
|April 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Aging cell·2026
Same author

Tristetraprolin protects against osteoarthritis by restraining chondrocyte mitochondrial DNA release through post-transcriptional regulation.

Journal of orthopaedic translation·2026
Same author

Temporal Trends and Cross-Country Inequalities in the Burden of Osteoarthritis, 1990-2021: Findings From the Global Burden of Disease Study 2021.

International journal of rheumatic diseases·2026
Same author

Corrigendum to 'Vitamins D and K jointly protect against osteoarthritis via regulating OSCAR during osteoclastogenesis' [J Orthop Transl <b>52</b> (2025) 387-403].

Journal of orthopaedic translation·2026
Same author

Associations of centrally acting analgesic use with total joint arthroplasty compared to selective serotonin reuptake inhibitor among osteoarthritis patients in a large prospective cohort.

BMC medicine·2026
Same author

Refining Osteoarthritis Risk Prediction: Average Sagittal Abdominal Diameter Complements and Enhances Body Mass Index With Sex-Specific Insights From National Health and Nutrition Examination Survey.

Health care science·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Chugai is developing MRA, an antibody targeting interleukin-6 (IL-6) receptors, for treating inflammatory conditions. This therapy is currently in phase II clinical trials for multiple myeloma and other IL-6 related disorders.

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Interleukin-6 (IL-6) is a key cytokine implicated in the pathogenesis of various inflammatory and autoimmune diseases.
  • Dysregulation of IL-6 signaling contributes to conditions such as multiple myeloma, rheumatoid arthritis, and Crohn's disease.

Purpose of the Study:

  • To evaluate the safety and efficacy of MRA, a humanized anti-IL-6 receptor monoclonal antibody.
  • To explore MRA's therapeutic potential in treating IL-6-related disorders.

Main Methods:

  • Development of a humanized monoclonal antibody (MRA) targeting the IL-6 receptor.
  • Conducting phase II clinical trials to assess MRA in patients with multiple myeloma, rheumatoid arthritis, Crohn's disease, and other relevant conditions.

Related Experiment Videos

Main Results:

  • MRA is currently undergoing phase II clinical trials, indicating promising preclinical or early clinical data.
  • The development focuses on blocking IL-6 receptor interaction, a critical pathway in inflammation.

Conclusions:

  • MRA represents a potential targeted therapy for a range of IL-6-mediated diseases.
  • Further clinical evaluation in phase II trials will determine MRA's efficacy and safety profile for patient treatment.